The development of new, targeted substances can replace classic chemotherapies with more tolerable approaches
1
. In this webcast, Marc Heizmann, MD, Senior Physician Hematology and Transfusion Medicine at the Cantonal Hospital Aarau, talks about the treatment guidelines for R/R CLL, presents studies on targeted therapy and presents two case reports.
Dr. sc. nat. Katja Becker
This article was produced with the financial support of AbbVie AG, Alte Steinhauserstrasse 14, Cham.
CH-VNCCLL-220057 08/2022
Brief technical information of Venclyxto®.
Literature
1. Bewarder et al. Current Treatment Options in CLL. Cancers (Basel). 2021 May 19;13(10):2468.
The references can be requested by professionals at medinfo.ch@abbvie.com .
